PriceTargets.com logo

Talphera - TLPH Stock Price Target and Predictions

  • Consensus Rating: Strong Buy
  • Consensus Price Target: $4.50
  • Forecasted Upside: 608.33%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 1 Strong Buy Ratings
$0.64 As of 12/20/2024 06:31 PM ET
▲ +0.0178 (2.88%)

This chart shows the closing price for TLPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Talphera Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TLPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TLPH

Analyst Price Target is $4.50
▲ +608.33% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Talphera in the last 3 months. The average price target is $4.50, with a high forecast of $6.00 and a low forecast of $3.00. The average price target represents a 608.33% upside from the last price of $0.64.

This chart shows the closing price for TLPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Strong Buy

The current consensus among 2 polled investment analysts is to buy (strong buy) stock in Talphera. This rating has held steady since October 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/8/2024Maxim GroupUpgradeStrong-Buy
8/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00
5/6/2024Maxim GroupInitiated CoverageBuy$3.00
3/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00
1/22/2024HC WainwrightBoost TargetBuy ➝ Buy$5.00 ➝ $6.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Talphera logo
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
Read More

Today's Range

Now: $0.64
Low: $0.60
High: $0.69

50 Day Range

MA: $0.80
Low: $0.61
High: $1.16

52 Week Range

Now: $0.64
Low: $0.60
High: $1.61

Volume

76,366 shs

Average Volume

91,024 shs

Market Capitalization

$10.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Talphera?

The following Wall Street analysts have issued reports on Talphera in the last year: HC Wainwright, and Maxim Group.
View the latest analyst ratings for TLPH.

What is the current price target for Talphera?

0 Wall Street analysts have set twelve-month price targets for Talphera in the last year. Their average twelve-month price target is $4.50, suggesting a possible upside of 608.3%. HC Wainwright has the highest price target set, predicting TLPH will reach $6.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $3.00 for Talphera in the next year.
View the latest price targets for TLPH.

What is the current consensus analyst rating for Talphera?

Talphera currently has 1 buy rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Strong Buy."
View the latest ratings for TLPH.

What other companies compete with Talphera?

Other companies that are similar to Talphera include Aileron Therapeutics, Virios Therapeutics, Cardio Diagnostics, BioVie and Passage Bio. Learn More about companies similar to Talphera.

How do I contact Talphera's investor relations team?

Talphera's physical mailing address is 1850 Gateway Drive, Suite 175, San Mateo, CA 94404, United States. The company's listed phone number is 650-216-3500 and its investor relations email address is [email protected]. The official website for Talphera is talphera.com. Learn More about contacing Talphera investor relations.